NIH News Release
NATIONAL INSTITUTES OF HEALTH
National Center for Complementary
and Alternative Medicine (NCCAM)


FOR IMMEDIATE RELEASE
Tuesday, July 6, 1999

Contact: Anita Greene
Telephone: (301) 496-1712

Federal Advisory Panel on Cancer and Alternative Medicine Chartered

Bethesda, Maryland — A federally chartered Cancer Advisory Panel on Complementary and Alternative Medicine (CAPCAM) has been established to provide advice and recommendations in the evaluation of complementary and alternative (CAM) therapies for cancer treatment and prevention.

The CAPCAM is a joint initiative of the National Center for Complementary and Alternative Medicine (NCCAM) and the National Cancer Institute (NCI). The Panel's key role is to serve in an advisory capacity to the NCCAM Director in the assessment of present and future CAM clinical trials and medical interventions, determine potential research opportunities, and develop a mechanism for communicating research results from these studies to key constituencies.

"The formulation of this panel of experts represents a vital step toward rigorously evaluating the efficacy and safety of various CAM cancer therapies that demonstrate the potential for helping to reduce the burden of this disease," said William Harlan, M.D., Acting Director of the NCCAM.

The CAPCAM will consist of 15 members (11 non-Federal members and 4 Federal members), including a chairperson who is appointed by the NIH Director. Panel members represent a broad range of expertise–including individuals who are knowledgeable in the fields of CAM or conventional medicine, including clinical trials, biostatistics, oncology, mediation, pathology, radiology, and bioethics, and who share a common interest in advancing research in this field. As a federally-charted advisory panel, the CAPCAM's activities are governed by the provisions of the Federal Advisory Committee Act (as amended).

Ernst L. Wynder, MD will serve as Chairman of the CAPCAM. Dr. Wynder is President and Medical Director of the American Health Foundation in New York, and Clinical Professor of Community and Preventive Medicine at New York Medical College. Dr. Wynder's research and education efforts have focused on the prevention and treatment of lung cancers. He has received numerous awards in his career, including the American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention. Dr. Wynder is a member of the board of Scientific Counselors for the Cancer Treatment Research Foundation and serves on the American Cancer Society's Policy Advisory Committee.

Listed is a roster of Cancer Advisory Panel on Complementary and Alternative Medicine members:

CHAIR:
Ernest Wynder, M.D.
President and Medical Director
American Health Foundation
New York, NY  
 
William R. Fair, M.D.
Director, Prostate Diagnostic Center
Attending Surgeon, Urology Oncology Services
Memorial Sloan-Kettering Cancer Center
New York, NY
 
June Brazil
Clinical Professional Associate
Acupuncture & Oriental Medicine Program
Mercy College
Dobbs Ferry, NY
 
James S. Gordon, M.D.
Director, Center for Mind-Body Medicine
Professor, Georgetown University School of Medicine
Washington, D.C.
Peter L. Choyke, M.D.
Chief, MRI
Diagnostic Radiology Department
Warren G. Magnuson Clinical Center, NIH
Bethesda, MD
 
Michael Hawkins, M.D.
Washington Cancer Institute
Washington Hospital Center
Washington, D.C.
Ian D. Coulter, Ph.D.
Research Professor and Health Consultant
RAND Corporation
Santa Monica, CA
 
 
David J. Hufford, Ph.D.
Professor, Medical Humanities, Behavioral Science, and Family Medicine
The Pennsylvania State University College of Medicine
Hershey, PA
Susan S. Ellenberg, Ph.D.
Director, Division of Biostatistics and Epidemiology
Center for Biology Evaluation and Research
Food and Drug Administration
Rockville, MD  
 
Frances A. Jacobs, R.N.
Clinical Nurse Coordinator
Rush-Presbyterian-St. Luke's Medical Center
Chicago, IL
Ralph W. Moss, PhD.
Director,
The Moss Reports
Brooklyn, NY
Douglas L. Weed, M.D., Ph.D.
Chief, Preventive Oncology Branch
Division of Cancer Prevention
National Cancer Institute, NIH
Bethesda, MD
Lauren V. Wood, M.D.
Senior Clinical Investigator
HIV & AIDS Malignancy Branch
National Cancer Institute, NIH
Bethesda, MD
 

Ad Hoc Members:
Mitchell R. Hammer, Ph.D.
The School of International Service
International Communication Program & Peace
and Conflict Resolution Program
American University
Washington, D.C.
 
 
Edward Chapman, M.D.
Newton, MA
 
Thomas Brown, M.D.
M.D. Anderson Cancer Center
Houston, TX
Ex-Officio Member:
Jeffrey D. White, Director
Office of Cancer Complementary and Alternative
Medicine, National Cancer Institute
Bethesda, MD

The first meeting of the CAPCAM will be held on July 8-9, 1999 at the Pooks Hill Marriott in Bethesda, Maryland. During this meeting, Panel members will assess research results from best case series and other clinical investigations on CAM therapies for cancer prevention and treatment. This meeting is open to the public. In accordance with Federal regulations governing advisory committees, a portion of the meeting (1:15 p.m. - 5:00 p.m.) in the afternoon of July 8, 1999 will be closed to the public to permit discussion of confidential research data from patient records.

To obtain an agenda for the CAPCAM meeting please call (301) 594-2013 or access this information electronically from the NCCAM's website at http://nccam.nih.gov.